Is FDA breakthrough therapy really valuable?
From the article:
In the recent New England Journal of Medicine, articles published by Harvard University's Jonathan Darrow, Jerry Avorn, and Aaron Kesselheim point out many of the issues arising from the "breakthrough therapies" of the US FDA and believe that reforms are needed; however, In this way, the FDA will still stick to its original position.
Read the full article here!